HK1008180A1 - Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism - Google Patents

Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism

Info

Publication number
HK1008180A1
HK1008180A1 HK98109130A HK98109130A HK1008180A1 HK 1008180 A1 HK1008180 A1 HK 1008180A1 HK 98109130 A HK98109130 A HK 98109130A HK 98109130 A HK98109130 A HK 98109130A HK 1008180 A1 HK1008180 A1 HK 1008180A1
Authority
HK
Hong Kong
Prior art keywords
vitamin
medicament
derivatives
manufacture
treatment
Prior art date
Application number
HK98109130A
Other languages
English (en)
Inventor
Joyce C Knutson
Richard B Mazess
Charles W Bishop
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23645881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1008180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Publication of HK1008180A1 publication Critical patent/HK1008180A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK98109130A 1995-04-03 1998-07-14 Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism HK1008180A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/415,488 US5602116A (en) 1988-08-02 1995-04-03 Method for treating and preventing secondary hyperparathyroidism
PCT/US1996/004553 WO1996031215A1 (en) 1995-04-03 1996-04-03 Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism

Publications (1)

Publication Number Publication Date
HK1008180A1 true HK1008180A1 (en) 1999-05-07

Family

ID=23645881

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98109130A HK1008180A1 (en) 1995-04-03 1998-07-14 Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism

Country Status (18)

Country Link
US (3) US5602116A (de)
EP (1) EP0820290B1 (de)
JP (1) JP3529790B2 (de)
KR (1) KR100432265B1 (de)
CN (1) CN1214795C (de)
AU (1) AU719773B2 (de)
BR (1) BR9604940A (de)
CA (1) CA2217260C (de)
DE (1) DE69629184T2 (de)
ES (1) ES2206570T3 (de)
FI (1) FI973868A0 (de)
HK (1) HK1008180A1 (de)
HU (1) HUP9801777A3 (de)
MX (1) MX9707535A (de)
NO (1) NO974480L (de)
NZ (1) NZ316662A (de)
PL (1) PL322613A1 (de)
WO (1) WO1996031215A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
BR9815442A (pt) * 1997-02-13 2001-08-21 Bone Care Int Inc Liberação terapêutica dirigida de compostos de vitamina d
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ES2368824T3 (es) * 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
EP1113804A2 (de) * 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Kombinationen des chroms oder des vanadiums mit antidiabetika für glukosemetabolismusstörungen
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
JP2003525254A (ja) * 2000-03-02 2003-08-26 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 併用化学療法
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
ES2266276T3 (es) * 2000-10-13 2007-03-01 Abbott Laboratories Un metodo para determinar la dosis de inicio de compuestos de vitamina d.
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
KR100438254B1 (ko) * 2001-03-29 2004-07-02 아이큐어 주식회사 비타민 ｄ 유사체를 포함하는 매트릭스형 경피흡수제제
ES2192136B1 (es) * 2002-01-04 2005-03-16 Italfarmaco, S.A. Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
US7566696B2 (en) 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
WO2004028515A1 (en) * 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CA2519189C (en) * 2003-05-07 2012-07-17 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
AU2004237438B2 (en) * 2003-05-07 2011-01-20 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
WO2005102355A1 (en) * 2004-04-23 2005-11-03 Genzyme Corporation METHODS OF TREATING VARIOUS VITAMIN D METABOLISM CONDITIONS WITH 1α-HYDROXYVITAMIN D2
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
JP2008530121A (ja) * 2005-02-14 2008-08-07 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 多発性硬化症を治療および予防するためのカルシトニンおよびカルシトニン様ペプチド類の使用
JP5303276B2 (ja) * 2005-10-12 2013-10-02 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー ２５−ヒドロキシビタミンｄ不足および欠乏を治療するための方法および製品
ES2699447T3 (es) * 2006-01-30 2019-02-11 Panion & Bf Biotech Inc Citrato férrico para revertir, prevenir, retrasar o estabilizar la calcificación de tejidos blandos
CA2882048C (en) * 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
DK3357496T3 (da) * 2006-06-21 2020-05-11 Opko Ireland Global Holdings Ltd Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel
US8987200B2 (en) * 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
EP2148683A4 (de) 2007-04-25 2012-09-12 Proventiv Therapeutics Llc Verfahren zur sicheren und wirksamen behandlung und prävention von sekundärer hyperparathyreose bei chronischer nierenerkrankung
ES2956794T3 (es) 2007-04-25 2023-12-28 Eirgen Pharma Ltd Liberación controlada de 25-hidroxivitamina D
US8592401B2 (en) * 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
KR101495578B1 (ko) * 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
EP2281058B1 (de) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Verfahren, zusammensetzungen, verwendungen und kits mit eignung bei vitamin-d-mangel und verwandten störungen
CN109223724A (zh) 2009-07-21 2019-01-18 凯克斯生物制药公司 柠檬酸铁剂型
CA2769525C (en) * 2009-07-29 2017-02-21 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US7886904B1 (en) * 2009-07-30 2011-02-15 Owens Corning Intellectual Capital, Llc Loosefill package for blowing wool machine
EP3636280A1 (de) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methoden und zusammensetzungen zur senkung von nebenschilddrüsenspiegeln
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
AU2011239488B2 (en) * 2010-04-16 2015-05-21 Baxter Healthcare S.A. Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
DK2717896T3 (en) 2011-06-08 2016-12-19 Kai Pharmaceuticals Inc Therapeutics for regulating phoshor serum
EP2776129B2 (de) 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Zusammensetzungen zur verwendung bei der behandlung von chronische renale osteodystrophie gekennzeichnet durch verkalkung der weichteile
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
DK3111934T3 (da) * 2014-02-26 2021-11-15 Nippon Zoki Pharmaceutical Co Progressions-hæmmende eller -forbedrende middel til kronisk nyresygdom
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP6520510B2 (ja) * 2015-07-15 2019-05-29 富士ゼロックス株式会社 情報処理装置及び情報処理プログラム
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907843A (en) * 1974-06-14 1975-09-23 Wisconsin Alumni Res Found 1{60 -Hydroxyergocalciferol and processes for preparing same
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
DE69132862T2 (de) * 1990-09-21 2002-08-29 Bone Care International Inc., Madison Neues 1alpha-hydroxy vitamin-d4 und neue zwischenprodukte und analoge
WO1992012165A1 (en) * 1991-01-08 1992-07-23 Lunar Corporation METHODS FOR PREPARATION AND USE OF 1α,24-DIHYDROXY VITAMIN D¿2?
DK0503630T3 (da) * 1991-03-13 1996-01-29 Kuraray Co Cyclohexantriolderivater
DE69318142T2 (de) * 1992-01-29 1998-09-17 Bone Care Int Inc 1 alpha-HYDROXY-24-(EPI)-VITAMIN D4
EP0562497A1 (de) * 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1-Alpha-Hydroxy-Vitamine D7 und D4', Verfahren zur ihren Herstellung und pharmazeutische Präparate davon
EP0614456B1 (de) * 1992-08-28 1999-06-09 Bone Care International, Inc. 1alpha,24(s)-dihydroxy vitamin d2, seine synthese und verwendung
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure

Also Published As

Publication number Publication date
FI973868A (fi) 1997-10-02
CA2217260C (en) 2000-08-01
ES2206570T3 (es) 2004-05-16
NO974480D0 (no) 1997-09-29
KR19980703537A (ko) 1998-11-05
JP3529790B2 (ja) 2004-05-24
AU5384096A (en) 1996-10-23
CA2217260A1 (en) 1996-10-10
US5707980A (en) 1998-01-13
BR9604940A (pt) 1998-06-09
CN1185109A (zh) 1998-06-17
EP0820290A1 (de) 1998-01-28
US5602116A (en) 1997-02-11
HUP9801777A2 (hu) 1998-11-30
DE69629184T2 (de) 2004-05-06
PL322613A1 (en) 1998-02-02
KR100432265B1 (ko) 2004-09-10
AU719773B2 (en) 2000-05-18
DE69629184D1 (de) 2003-08-28
EP0820290B1 (de) 2003-07-23
CN1214795C (zh) 2005-08-17
JPH11503164A (ja) 1999-03-23
HUP9801777A3 (en) 1999-05-28
FI973868A0 (fi) 1997-10-02
NZ316662A (en) 2001-04-27
NO974480L (no) 1997-11-14
US5861386A (en) 1999-01-19
MX9707535A (es) 1998-07-31
WO1996031215A1 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
FR05C0027I2 (de)
HK1041489A1 (en) 5-0-Desosaminyl 6-0-methylerythronolide a for use for the preparation of bilogically-active products
EP0740937A3 (de) Verwendung der Retinoide zur Herstellung einer pharmazeutischen oder kosmetischen Zusammensetzung
HK1005425A1 (en) Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis
AU5802196A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers
ZA966985B (en) A rapidly disintegrating medicinal form of tramadol or a tramadol salt.
AU4517893A (en) An oral formulation for gastric antibacterial treatment as well as a process thereof and the use
AU4705193A (en) Medicaments for the treatment or prevention of elevated intraocular pressure
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
HUP9901303A3 (en) A pharmaceutical composition for the treatment of autoimmune diseases
EP0765661A3 (de) Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung von Glomerulonephritis
AU2739497A (en) Use of vitamin d analogs for the treatment of arthritic disease
GB9303157D0 (en) Treatment of a group of related disorders
AU1348895A (en) Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders
EP0790062A4 (de) Medikament gegen herzerkrankungen
IL113057A0 (en) Compositions for the treatment of dandruff
AU5627796A (en) Medicaments for the treatment or prophylaxis of ischemia-reperfusion injury
HUP9800334A3 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
AU4081393A (en) Medicaments for the treatment of anxiety
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
GB2316614B (en) Composition for a dietary supplement for the treatment of hemorrhoids

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20160402